RARE INSPIRATION. CHANGING LIVES.

ALEXION®
AstraZeneca Rare Disease

Every Day
Is An Inspiration

People affected by rare diseases and devastating conditions are our inspiration and our Guiding Star.

Our mission is to transform their lives through the development and delivery of innovative medicines, as well as through supportive technologies and healthcare services. We believe it is our responsibility to listen to, understand, and change the lives of patients and those who work tirelessly to help them.





OUR 30 YEAR JOURNEY

1992
Alexion founded in New Haven, CT

1996
Alexion goes public with ticker ALXN

2007
SOLIRIS® (eculizumab) first approved for the treatment of patients with PNH

2011
SOLIRIS first approved for the treatment of patients with aHUS

2012
Acquired asfotase alfa, a potential treatment for patients living with HPP

2015
Acquired Synageva and added to its pipeline sebelipase alfa, a potential treatment for patients living with LAL-D

2015
STRENSIQ® (asfotase alfa) first approved for the treatment of patients with HPP

2015
KANUMA® (sebelipase alfa) first approved for the treatment of patients with LAL-D

2016
Opened Center of Excellence in New Haven

2017
SOLIRIS first approved for the treatment of patients with gMG

2017
Partnered with Halozyme Therapeutics and established license agreement for ENHANZE® drug-delivery technology

2018
Opened global headquarters in Boston

2018
Acquired Wilson Therapeutics, the company that developed ALXN1840 (WTX101) for the treatment of Wilson Disease

2018
Acquired Syntimmune, the company that began development of ALXN1830 (SYNT001) for the treatment of rare IgG-mediated diseases

2018
Established partnerships with Complement Pharma and Dicerna

2018
ULTOMIRIS® (ravulizumab-cwvz) first approved for the treatment of adult patients with PNH

2019
Established partnerships with Caelum Biosciences and Zealand Pharma

2019
SOLIRIS first approved for the treatment of adult patients with NMOSD

2019
Announced Japanese license agreement with BridgeBio to develop and commercialize acoramidis (ALXN2060) in Japan for transthyretin amyloid cardiomyopathy (ATTR-CM)

2019
ULTOMIRIS first approved for the treatment of adults and pediatric patients one month of age and older with aHUS to inhibit complement-mediated thrombotic microangiopathy (TMA)

2020
Acquired Achillion, a biopharmaceutical company focused on the development of oral small molecule Factor D inhibitors to treat people with complement alternative pathway-mediated rare diseases

2020
Acquired Portola, a commercial-stage biopharmaceutical company focused on life-threatening blood-related disorders, adding Andexxa® (marketed as Ondexxya® in Europe) to its growing acute care portfolio

2021
Alexion acquired by AstraZeneca. The AstraZeneca group focusing on rare diseases is created and named Alexion, AstraZeneca Rare Disease.

APPROVALS ACQUISITIONS PARTNERSHIPS

ALEXION BY THE NUMBERS

4
PRIX GALIEN AWARDS

30
YEARS OF LEADERSHIP IN RARE DISEASE

5
APPROVED THERAPIES

7
RARE DISEASES & DEVASTATING CONDITIONS

SERVING PATIENTS IN
50
COUNTRIES

ULTOMIRIS® (ravulizumab-cwvz) injection for intravenous use 300 mg/30 mL vial

FOR

PNH

aHUS

SOLIRIS® (eculizumab) Injection for Intravenous Use 300 mg/30 mL vial

FOR

PNH

aHUS

gMG

NMOSD

Strensiq® (asfotase alfa) For injection 40 mg/mL

FOR

HPP

Kanuma® (sebelipase alfa) intravenous infusion 20mg/10mL

FOR

LAL-D

Koselugo® (selumetinib) 10mg & 25mg capsules

FOR

NF1 PN